Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOXY-3 Study (3-Day Doxycycline for Chlamydia trachomatis)
jRCTs031240353Active, not recruiting
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of doxycycline in Chlamydia trachomatis infection. Primary endpoint: Treatment success rate at 28 days post-treatment (all sites). Started Oct 2024; status: active, not recruiting.
02
Drugs
doxycycline
03
Conditions
Chlamydia trachomatis infection
Beyond the preview
Go deeper on jRCTs031240353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240353.